Trevi Therapeutics将1亿美元股票定价为每股5.75美元

• Clinical-stage biopharmaceutical company Trevi Therapeutics (NASDAQ:TRVI) priced previously announced underwritten public offering of 17.4M shares at a public offering price of $5.75 per share.
• Total proceeds are expected to be $100M.
• Underwriters have a 30-day option to purchase up to 2.61M additional shares.
• The offering is expected to close on or about June 5, 2025.

More on Trevi Therapeutics

• Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript
• Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript
• Trevi Therapeutics GAAP EPS of -$0.09 beats by $0.03
• Trevi Therapeutics meets main goal in chronic coughing treatment trial, stock surges
• Seeking Alpha’s Quant Rating on Trevi Therapeutics